Drug
Fasudil hydrochloride
Fasudil hydrochloride is a pharmaceutical drug with 5 clinical trials. Currently 2 active trials ongoing. Historical success rate of 50.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
2(40%)
Results Posted
200%(2 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_4
1
20%
Ph phase_2
4
80%
Phase Distribution
0
Early Stage
4
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
Phase 4Post-market surveillance
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(1)
Terminated(1)
Other(1)
Detailed Status
Recruiting2
Completed1
Terminated1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
2
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Phase 24 (80.0%)
Phase 41 (20.0%)
Trials by Status
completed120%
recruiting240%
terminated120%
unknown120%
Recent Activity
2 active trials
Showing 5 of 5
recruitingphase_2
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease
NCT05931575
recruitingphase_2
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer
NCT06890858
completedphase_2
Red Blood Cell ATP Release and Vascular Function in Humans
NCT03404843
unknownphase_4
Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction
NCT03753269
terminatedphase_2
Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis
NCT00670202
Clinical Trials (5)
Showing 5 of 5 trials
NCT05931575Phase 2
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease
NCT06890858Phase 2
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer
NCT03404843Phase 2
Red Blood Cell ATP Release and Vascular Function in Humans
NCT03753269Phase 4
Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction
NCT00670202Phase 2
Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5